Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LDHA | P00338 | 1/20 | 0.51 |
| ▸ | BACE1 | P56817 | 2/20 | 0.48 |
| ▸ | PPARA | Q07869 | 4/20 | 0.48 |
| ▸ | PPARG | P37231 | 4/20 | 0.48 |
| ▸ | FFAR1 | O14842 | 3/20 | 0.45 |
| ▸ | CACNA1A | O00555 | 1/20 | 0.44 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.44 |
| ▸ | CACNB1 | Q02641 | 1/20 | 0.44 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.44 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.44 |
| ▸ | PPARD | Q03181 | 1/20 | 0.43 |
| ▸ | BMP1 | P13497 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5754309 | 0.86 | PPARG (0.53) | PPARAPPARGFFAR1 | |
| SCHEMBL5749180 | 0.86 | LDHA (0.55) | LDHAPPARAPPARGFFAR1 | |
| SCHEMBL5751624 | 0.84 | PPARG (0.44) | PPARAPPARGAKR1C3AKR1C2 | |
| SCHEMBL5749682 | 0.84 | PPARG (0.44) | PPARAPPARGAKR1C3AKR1C2 | |
| SCHEMBL5750437 | 0.84 | PPARG (0.51) | PPARAPPARG | |
| SCHEMBL5753842 | 0.83 | PPARG (0.57) | PPARAPPARGFFAR1 | |
| SCHEMBL1154169 | 0.83 | LDHA (0.55) | LDHABACE1PPARAPPARGFFAR1 | |
| SCHEMBL5750572 | 0.82 | PPARA (0.43) | PPARAPPARGFFAR1 | |
| SCHEMBL5751819 | 0.81 | CYP2D6 (0.51) | LDHABACE1PPARAPPARGFFAR1 | |
| SCHEMBL5751870 | 0.79 | AKR1C3 (0.47) | PPARAPPARGFFAR1AKR1C3AKR1C2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6982348-B2 | Aminoethanol derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-01-03 | — | — | US | disclosed |
| US-20040127574-A1 | Aminoethanol derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-07-01 | — | — | US | disclosed |
| EP-1362846-A1 | AMINOETHANOL DERIVATIVES | Takeda Chemical Industries, Ltd. (JP) | 2003-11-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040127574-A1 | Aminoethanol derivatives | CETP, LCAT, MTTP | LDHA 3190/4885BACE1 835/4885PPARA 708/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.